Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971930 · ClinicalTrials.gov registry record
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 30
- Enrollment target
NCT02971930: Completed study, sponsored by Bayer.
NCT02971930 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02971930 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients' satisfaction with treatment and their quality of life.
Primary Outcome
To conduct qualitative interviews with patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences satisfaction
Interventions
- BIOLOGICAL BAY94-9027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-06-20 |
| Est. Completion | 2017-12-15 |
What the finished NCT02971930 record still lists
NCT02971930 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which BAY94-9027 is the first listed.
NCT02971930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02971930 about?
NCT02971930 is a clinical study titled "Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A". This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients' satisfaction with treatment and their quality of life.
What is the current status of trial NCT02971930?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2017-06-20. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT02971930?
The interventions under investigation include: BAY94-9027 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02971930?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI